Chiappori, Alberto A.
Williams, Charles C.
Gray, Jhanelle E.
Tanvetyanon, Tawee
Haura, Eric B.
Creelan, Ben C.
Thapa, Ram
Chen, Dung-Tsa
Simon, George R.
Bepler, Gerold
Gabrilovich, Dmitry I.
Antonia, Scott J.
Funding for this research was provided by:
National Institutes of Health (5 P50 CA119997)
National Cancer Institute (P30-CA076292)
Article History
Received: 15 May 2018
Accepted: 11 December 2018
First Online: 27 December 2018
Compliance with ethical standards
:
: Scott Antonia discloses an unlicensed patent on the vaccine. All other authors declare that they have no conflicts of interest.
: The study protocol was approved by the National Institutes of Health Office of Biotechnology Activities (0705-857), the Food and Drug Administration (Investigational New Drug BB-IND-9792), and the University of South Florida’s Institutional Review Board and Institutional Biosafety Committee (Pro00007665). The ClinicalTrials.gov identifier is NCT00617409. The study was conducted in accordance with Good Clinical Practice.
: Informed consent was obtained from all individual participants included in the study, each of whom signed an informed consent document before enrollment. The patients consented to the use of their data for research and publication purposes.